DD157343A5 - Mikrobielle expression von quasi-synthetischen genen - Google Patents
Mikrobielle expression von quasi-synthetischen genen Download PDFInfo
- Publication number
- DD157343A5 DD157343A5 DD80222413A DD22241380A DD157343A5 DD 157343 A5 DD157343 A5 DD 157343A5 DD 80222413 A DD80222413 A DD 80222413A DD 22241380 A DD22241380 A DD 22241380A DD 157343 A5 DD157343 A5 DD 157343A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- fragment
- polypeptide
- item
- amino acid
- expression
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 82
- 230000014509 gene expression Effects 0.000 title claims abstract description 45
- 230000000813 microbial effect Effects 0.000 title claims abstract description 12
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 50
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 49
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 13
- 238000010839 reverse transcription Methods 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims description 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 35
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 108020004705 Codon Proteins 0.000 claims description 25
- 101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 claims description 24
- 239000013599 cloning vector Substances 0.000 claims description 22
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 230000003362 replicative effect Effects 0.000 claims description 12
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 claims description 7
- 239000000122 growth hormone Substances 0.000 claims description 7
- 208000016861 hereditary angioedema type 3 Diseases 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000018997 Growth Hormone Human genes 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- 108700005078 Synthetic Genes Proteins 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000470 constituent Substances 0.000 claims 2
- 238000010276 construction Methods 0.000 abstract description 13
- 238000005520 cutting process Methods 0.000 abstract description 8
- 230000000975 bioactive effect Effects 0.000 abstract description 6
- 206010013883 Dwarfism Diseases 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000002255 enzymatic effect Effects 0.000 abstract description 3
- 208000003068 pituitary dwarfism Diseases 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 16
- 239000013598 vector Substances 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000005556 hormone Substances 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 108090000364 Ligases Proteins 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000015731 Peptide Hormones Human genes 0.000 description 2
- 108010038988 Peptide Hormones Proteins 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- -1 antibodies Proteins 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000002607 Pseudarthrosis Diseases 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/055,126 US4342832A (en) | 1979-07-05 | 1979-07-05 | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD157343A5 true DD157343A5 (de) | 1982-11-03 |
Family
ID=26733870
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD80244147A DD210070A5 (de) | 1979-07-05 | 1980-07-04 | Verfahren zur herstellung eines polypeptids |
| DD80244149A DD210071A5 (de) | 1979-07-05 | 1980-07-04 | Verfahren zur herstellung einer lebensfaehigen kultur |
| DD80222413A DD157343A5 (de) | 1979-07-05 | 1980-07-04 | Mikrobielle expression von quasi-synthetischen genen |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD80244147A DD210070A5 (de) | 1979-07-05 | 1980-07-04 | Verfahren zur herstellung eines polypeptids |
| DD80244149A DD210071A5 (de) | 1979-07-05 | 1980-07-04 | Verfahren zur herstellung einer lebensfaehigen kultur |
Country Status (42)
| Country | Link |
|---|---|
| US (7) | US4342832A (pt) |
| EP (1) | EP0022242B1 (pt) |
| JP (4) | JPH0612996B2 (pt) |
| KR (2) | KR830003574A (pt) |
| AR (1) | AR244341A1 (pt) |
| AT (1) | ATE82324T1 (pt) |
| AU (2) | AU533697B2 (pt) |
| BE (1) | BE884012A (pt) |
| BG (1) | BG41135A3 (pt) |
| BR (1) | BR8008736A (pt) |
| CA (2) | CA1164375A (pt) |
| CH (1) | CH661939A5 (pt) |
| CS (3) | CS250652B2 (pt) |
| DD (3) | DD210070A5 (pt) |
| DE (3) | DE3023627A1 (pt) |
| DK (2) | DK173503B1 (pt) |
| EG (1) | EG14819A (pt) |
| ES (2) | ES8105386A1 (pt) |
| FI (2) | FI802030A (pt) |
| FR (2) | FR2460330B1 (pt) |
| GB (2) | GB2121047B (pt) |
| GR (1) | GR69320B (pt) |
| HK (3) | HK87484A (pt) |
| IE (3) | IE50460B1 (pt) |
| IL (3) | IL69492A (pt) |
| IT (1) | IT1131393B (pt) |
| KE (3) | KE3451A (pt) |
| MX (1) | MX172674B (pt) |
| MY (3) | MY8500765A (pt) |
| NL (1) | NL930114I2 (pt) |
| NO (2) | NO167673C (pt) |
| NZ (2) | NZ201312A (pt) |
| OA (1) | OA06562A (pt) |
| PH (1) | PH19814A (pt) |
| PL (1) | PL149278B1 (pt) |
| PT (1) | PT71487A (pt) |
| RO (1) | RO93374B (pt) |
| SG (1) | SG56984G (pt) |
| WO (1) | WO1981000114A1 (pt) |
| YU (3) | YU163580A (pt) |
| ZA (1) | ZA803600B (pt) |
| ZW (1) | ZW14180A1 (pt) |
Families Citing this family (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898830A (en) * | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US6455275B1 (en) | 1980-02-25 | 2002-09-24 | The Trustees Of Columbia University In The City Of New York | DNA construct for producing proteinaceous materials in eucaryotic cells |
| CA1200773A (en) * | 1980-02-29 | 1986-02-18 | William J. Rutter | Expression linkers |
| US4711843A (en) * | 1980-12-31 | 1987-12-08 | Cetus Corporation | Method and vector organism for controlled accumulation of cloned heterologous gene products in Bacillus subtilis |
| ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| IL59690A (en) * | 1980-03-24 | 1983-11-30 | Yeda Res & Dev | Production of bovine growth hormone by microorganisms and modified microorganisms adapted to produce it |
| US4370417A (en) * | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
| US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| DK339781A (da) * | 1980-08-05 | 1982-02-06 | Searle & Co | Syntetisk gen |
| US7101981B1 (en) | 1980-08-26 | 2006-09-05 | Regents Of The University Of California | Bovine growth hormone recombinantly produced in E. coli |
| US4725549A (en) * | 1980-09-22 | 1988-02-16 | The Regents Of The University Of California | Human and rat prolactin and preprolactin cloned genes |
| GR81946B (pt) * | 1980-09-25 | 1984-12-12 | Genentech Inc | |
| NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| JPS57181098A (en) * | 1981-04-30 | 1982-11-08 | Japan Found Cancer | Novel recombinant dna |
| US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| US4810645A (en) * | 1981-08-14 | 1989-03-07 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| NZ201918A (en) * | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4880910A (en) * | 1981-09-18 | 1989-11-14 | Genentech, Inc. | Terminal methionyl bovine growth hormone and its use |
| US5254463A (en) * | 1981-09-18 | 1993-10-19 | Genentech, Inc. | Method for expression of bovine growth hormone |
| US5236831A (en) * | 1981-12-29 | 1993-08-17 | Kiowa Hakko Kogyo Co., Ltd. | Amino acid synthesis in corynebacteria using E. coli genes |
| US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US4665160A (en) * | 1982-03-22 | 1987-05-12 | Genentech, Inc. | Novel human growth hormone like protein HGH-V encoded in the human genome |
| US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4652639A (en) * | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| EP0095361B1 (en) * | 1982-05-25 | 1989-07-26 | Eli Lilly And Company | Cloning vectors for expression of exogenous protein |
| US4778759A (en) * | 1982-07-09 | 1988-10-18 | Boyce, Thompson Institute For Plant Research, Inc. | Genetic engineering in cyanobacteria |
| US4891315A (en) * | 1982-10-25 | 1990-01-02 | American Cyanamid Company | Production of herpes simplex viral porteins |
| JPS59501533A (ja) * | 1982-08-10 | 1984-08-30 | ザ トラステイ− オブ コロンビア ユニバ−シテイ− イン ザ シテイ オブ ニユ− ヨ−ク | 蛋白質様物質の製造における真生核促進体連鎖の使用 |
| US4530904A (en) * | 1982-09-03 | 1985-07-23 | Eli Lilly And Company | Method for conferring bacteriophage resistance to bacteria |
| WO1984001150A1 (en) * | 1982-09-16 | 1984-03-29 | Amgen | Avian growth hormones |
| CA1209501A (en) * | 1982-09-16 | 1986-08-12 | Nikos Panayotatos | Expression vector |
| US4666839A (en) * | 1982-12-01 | 1987-05-19 | Amgen | Methods and materials for obtaining microbial expression of polypeptides including bovine prolactin |
| JPS59106297A (ja) * | 1982-12-07 | 1984-06-19 | Rikagaku Kenkyusho | ヒト生長ホルモンのカルボキシ末端遺伝子の合成法 |
| US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| DK55685A (da) * | 1985-02-07 | 1986-08-08 | Nordisk Gentofte | Enzym eller enzymkompleks med proteolytisk aktivitet |
| US4634678A (en) * | 1982-12-13 | 1987-01-06 | Molecular Genetics Research And Development Limited Partnership | Plasmid cloning and expression vectors for use in microorganisms |
| GB8303383D0 (en) * | 1983-02-08 | 1983-03-16 | Biogen Nv | Sequences recombinant dna molecules |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4859600A (en) * | 1983-04-25 | 1989-08-22 | Genentech, Inc. | Recombinant procaryotic cell containing correctly processed human growth hormone |
| US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| BG49718A3 (en) * | 1983-07-15 | 1992-01-15 | Bio- Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
| US4900811A (en) * | 1983-07-21 | 1990-02-13 | Scripps Clinic And Research Foundation | Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same |
| US5242798A (en) * | 1983-07-21 | 1993-09-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same |
| JPS60137291A (ja) * | 1983-12-26 | 1985-07-20 | Takeda Chem Ind Ltd | 発現ベクター |
| CA1213537A (en) * | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
| CA1272144A (en) * | 1984-06-29 | 1990-07-31 | Tamio Mizukami | Fish growth hormone polypeptide |
| US5489529A (en) * | 1984-07-19 | 1996-02-06 | De Boer; Herman A. | DNA for expression of bovine growth hormone |
| WO1986002068A1 (en) * | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
| US4680262A (en) * | 1984-10-05 | 1987-07-14 | Genentech, Inc. | Periplasmic protein recovery |
| DE3586386T2 (de) * | 1984-10-05 | 1993-01-14 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| NZ213759A (en) * | 1984-10-19 | 1989-01-27 | Genentech Inc | Lhrh-ctp protein conjugates influencing prolactin fsh and lh release |
| US4645829A (en) * | 1984-10-29 | 1987-02-24 | Monsanto Company | Method for separating polypeptides |
| US4861868A (en) * | 1985-02-22 | 1989-08-29 | Monsanto Company | Production of proteins in procaryotes |
| US4652630A (en) * | 1985-02-22 | 1987-03-24 | Monsanto Company | Method of somatotropin naturation |
| DK151585D0 (da) * | 1985-04-03 | 1985-04-03 | Nordisk Gentofte | Dna-sekvens |
| EP0200986B2 (en) * | 1985-04-25 | 1998-03-11 | F. Hoffmann-La Roche Ag | Recombinant human interleukin-1 |
| DE3681787D1 (de) * | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| US5041381A (en) | 1986-07-03 | 1991-08-20 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
| US4892764A (en) * | 1985-11-26 | 1990-01-09 | Loctite Corporation | Fiber/resin composites, and method of making the same |
| US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
| US5827826A (en) * | 1986-03-03 | 1998-10-27 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compositions of human endothelial cell growth factor |
| ES2061524T3 (es) * | 1986-05-07 | 1994-12-16 | Eniricerche Spa | Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona. |
| EP0252588A3 (en) * | 1986-05-12 | 1989-07-12 | Smithkline Beecham Corporation | Process for the isolation and purification of p. falciparum cs protein expressed in recombinant e. coli, and its use as a vaccine |
| US4806239A (en) * | 1986-11-28 | 1989-02-21 | Envirotech Corporation | Apparatus for shifting filter plates in a filter press |
| JPS63159244A (ja) * | 1986-12-23 | 1988-07-02 | 三菱マテリアル株式会社 | 二層の押出成形珪酸質―石灰質系成形品の製造方法 |
| DE3751144D1 (de) * | 1986-12-31 | 1995-04-13 | Lucky Ltd | Verfahren zur herstellung eines lachswachstumshormons mittels eines kunstgens. |
| EP0329710A1 (en) * | 1987-01-07 | 1989-08-30 | Allied Corporation | Microbial production of peptide oligomers |
| US4977089A (en) * | 1987-01-30 | 1990-12-11 | Eli Lilly And Company | Vector comprising signal peptide-encoding DNA for use in Bacillus and other microorganisms |
| WO1988010119A1 (en) * | 1987-06-22 | 1988-12-29 | Genetics Institute, Inc. | Novel thrombolytic proteins |
| FR2624835B2 (fr) * | 1987-08-05 | 1990-09-07 | Hassevelde Roger | Support ergonomique a creme glacee, a cuillere integree, transformable en tout autre objet apres son utilisation premiere |
| US5268267A (en) * | 1987-08-21 | 1993-12-07 | The General Hospital Corporation | Method for diagnosing small cell carcinoma |
| IT1223577B (it) * | 1987-12-22 | 1990-09-19 | Eniricerche Spa | Procedimento migliorato per la preparazione dell'ormone della crescita umano naturale in forma pura |
| JPH0231042U (pt) * | 1988-08-19 | 1990-02-27 | ||
| US5130422A (en) * | 1988-08-29 | 1992-07-14 | Monsanto Company | Variant somatotropin-encoding DNA |
| DE68928124T2 (de) | 1988-09-02 | 1997-10-16 | Chiron Corp., Emeryville, Calif. | Makrophagenabgeleiteter entzündungsmediator(mip-2) |
| US5079230A (en) * | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
| US5082767A (en) * | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| US5075227A (en) * | 1989-03-07 | 1991-12-24 | Zymogenetics, Inc. | Directional cloning |
| US4960301A (en) * | 1989-03-27 | 1990-10-02 | Fry Steven A | Disposable liner for pickup truck beds |
| US5164180A (en) | 1989-05-18 | 1992-11-17 | Mycogen Corporation | Bacillus thuringiensis isolates active against lepidopteran pests |
| US5266477A (en) * | 1990-02-02 | 1993-11-30 | Pitman-Moore, Inc. | Monoclonal antibodies which differentiate between native and modified porcine somatotropins |
| CA2041446A1 (en) | 1990-05-15 | 1991-11-16 | August J. Sick | Bacillus thuringiensis genes encoding novel dipteran-active toxins |
| US5849694A (en) * | 1990-07-16 | 1998-12-15 | Synenki; Richard M. | Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof |
| US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
| US5744139A (en) * | 1991-06-28 | 1998-04-28 | University Of Tennessee Research Corporation | Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios |
| HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
| US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| US5317012A (en) * | 1991-10-04 | 1994-05-31 | The University Of Tennessee Research Corporation | Human growth hormone induced improvement in depressed T4/T8 ratio |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1994008611A1 (en) * | 1992-10-22 | 1994-04-28 | Sloan-Kettering Institute For Cancer Research | GROWTH HORMONE FRAGMENT hGH 108-129 |
| EP1281770B1 (en) | 1993-03-10 | 2010-03-03 | GlaxoSmithKline LLC | Human brain phosphodiesterase and screening method |
| FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US5760187A (en) * | 1996-02-22 | 1998-06-02 | Mitsui Toatsu Chemicals, Inc. | Purification process of a human growth hormone |
| JP3794748B2 (ja) * | 1996-03-04 | 2006-07-12 | 第一アスビオファーマ株式会社 | メタノール代謝系を有する微生物の培養法 |
| US6503729B1 (en) | 1996-08-22 | 2003-01-07 | The Board Of Trustees Of The University Of Illinois | Selected polynucleotide and polypeptide sequences of the methanogenic archaeon, methanococcus jannashii |
| MX9605082A (es) * | 1996-10-24 | 1998-04-30 | Univ Autonoma De Nuevo Leon | Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano. |
| EP1007069A1 (en) * | 1996-11-01 | 2000-06-14 | Smithkline Beecham Corporation | Novel coding sequences |
| US6068991A (en) * | 1997-12-16 | 2000-05-30 | Bristol-Myers Squibb Company | High expression Escherichia coli expression vector |
| EP1749834B1 (en) | 1997-12-18 | 2012-04-25 | Monsanto Technology LLC | Insect-resistant transgenic plants and methods for improving delta-endotoxin activity against target insects |
| US6087128A (en) | 1998-02-12 | 2000-07-11 | Ndsu Research Foundation | DNA encoding an avian E. coli iss |
| CA2324513C (en) | 1998-03-31 | 2013-05-28 | Tonghua Gantech Biotechnology Ltd. | Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production |
| US6512162B2 (en) | 1998-07-10 | 2003-01-28 | Calgene Llc | Expression of eukaryotic peptides in plant plastids |
| US6271444B1 (en) | 1998-07-10 | 2001-08-07 | Calgene Llc | Enhancer elements for increased translation in plant plastids |
| EP1117478B1 (de) | 1998-08-28 | 2005-06-01 | Febit AG | Träger für analytbestimmungsverfahren und verfahren zur herstellung des trägers |
| US6586211B1 (en) | 1999-02-19 | 2003-07-01 | Febit Ferrarius Biotechnology Gmbh | Method for producing polymers |
| US6946265B1 (en) | 1999-05-12 | 2005-09-20 | Xencor, Inc. | Nucleic acids and proteins with growth hormone activity |
| US6187750B1 (en) | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| US6562790B2 (en) | 2000-02-05 | 2003-05-13 | Chein Edmund Y M | Hormone therapy methods and hormone products for abating coronary artery blockage |
| CA2405557C (en) | 2000-04-12 | 2013-09-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6995246B1 (en) * | 2000-10-19 | 2006-02-07 | Akzo Nobel N.V. | Methods for removing suspended particles from soluble protein solutions |
| WO2002043709A1 (fr) | 2000-12-01 | 2002-06-06 | Takeda Chemical Industries, Ltd. | Procede de production d'une preparation contenant une substance bioactive |
| US20030049731A1 (en) * | 2000-12-05 | 2003-03-13 | Bowdish Katherine S. | Engineered plasmids and their use for in situ production of genes |
| US20020164712A1 (en) * | 2000-12-11 | 2002-11-07 | Tonghua Gantech Biotechnology Ltd. | Chimeric protein containing an intramolecular chaperone-like sequence |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| US6720538B2 (en) * | 2001-06-18 | 2004-04-13 | Homedics, Inc. | Thermostat variation compensating knob |
| DK1578771T3 (da) | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodellering og glycokonjugering af peptider |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2343518T3 (es) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
| TWI281864B (en) * | 2002-11-20 | 2007-06-01 | Pharmacia Corp | N-terminally monopegylated human growth hormone conjugates and process for their preparation |
| EP2460530A3 (en) | 2002-12-31 | 2012-08-29 | Althea Technologies, Inc. | Human growth hormone crystals and methods for preparing them |
| EP1597299A2 (en) * | 2003-02-19 | 2005-11-23 | Pharmacia Corporation | Carbonate esters of polyethylene glycol activated by means of oxalate esters |
| AU2004235875A1 (en) * | 2003-05-09 | 2004-11-18 | Pharmexa A/S | Immunogenic human TNF alpha analogues with reduced cytotoxicity and methods of their preparation |
| WO2005074546A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| CA2558760A1 (en) * | 2004-06-23 | 2006-01-05 | Usv Limited | Chimeric human growth hormone derived from the placenta and pituitary isoform and processes for obtaining said chimera |
| US20060024288A1 (en) * | 2004-08-02 | 2006-02-02 | Pfizer Inc. | tRNA synthetase fragments |
| US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
| NZ555206A (en) | 2004-12-22 | 2010-09-30 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| US7939496B2 (en) | 2004-12-22 | 2011-05-10 | Ambrx, Inc. | Modified human growth horomone polypeptides and their uses |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
| US8030271B2 (en) * | 2005-07-05 | 2011-10-04 | Emisphere Technologies, Inc. | Compositions and methods for buccal delivery of human growth hormone |
| US20100010068A1 (en) * | 2005-08-19 | 2010-01-14 | Binhai Ren | Liver-directed gene therapy |
| PT2339014E (pt) | 2005-11-16 | 2015-10-13 | Ambrx Inc | Métodos e composições compreendendo aminoácidos não-naturais |
| EP1976551A4 (en) * | 2005-12-23 | 2009-12-30 | Altus Pharmaceuticals Inc | COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF |
| DE102006039479A1 (de) | 2006-08-23 | 2008-03-06 | Febit Biotech Gmbh | Programmierbare Oligonukleotidsynthese |
| AU2007333959A1 (en) | 2006-12-18 | 2008-06-26 | Altus Pharmaceuticals Inc. | Human growth hormone formulations |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| WO2009014782A2 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| JP2010525812A (ja) | 2007-05-02 | 2010-07-29 | メリアル リミテッド | 発現及び安定性が改善されたｄｎａプラスミド |
| WO2009012502A1 (en) * | 2007-07-19 | 2009-01-22 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Self- anchoring mems intrafascicular neural electrode |
| US7939447B2 (en) * | 2007-10-26 | 2011-05-10 | Asm America, Inc. | Inhibitors for selective deposition of silicon containing films |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| HUE054585T2 (hu) | 2008-04-29 | 2021-09-28 | Ascendis Pharma Endocrinology Div A/S | Pegilezett rekombináns humán növekedési hormon vegyületek |
| SG2014015010A (en) * | 2008-04-30 | 2014-05-29 | Gradalis Inc | Highly pure plasmid dna preparations and processes for preparing the same |
| BRPI0822826A2 (pt) | 2008-06-25 | 2015-07-07 | Braasch Biotech Llc | Proteína de fusão de somatostatina deficiente em cloranfenicol acetil trasferase (cat) e seus usos |
| CN102119033B (zh) * | 2008-06-25 | 2015-04-08 | 布拉施生物技术有限责任公司 | 用于增强促生长素抑制素免疫原性的组合物和方法 |
| US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| CA2748314C (en) | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| US20100216648A1 (en) | 2009-02-20 | 2010-08-26 | Febit Holding Gmbh | Synthesis of sequence-verified nucleic acids |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| AU2010290131C1 (en) | 2009-08-24 | 2015-12-03 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| KR20120123365A (ko) | 2009-12-21 | 2012-11-08 | 암브룩스, 인코포레이티드 | 변형된 돼지 소마토트로핀 폴리펩티드 및 이의 용도 |
| CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
| EP2536749A1 (en) | 2010-02-17 | 2012-12-26 | Elona Biotechnologies | Methods for preparing human growth hormone |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| WO2012097333A2 (en) | 2011-01-14 | 2012-07-19 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
| RU2473556C1 (ru) * | 2011-07-14 | 2013-01-27 | Закрытое акционерное общество "ГЕНЕРИУМ" | Промышленный способ получения и очистки рекомбинантного гормона роста человека из телец включения |
| MX367842B (es) | 2012-02-07 | 2019-09-09 | Global Bio Therapeutics Inc | Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo. |
| DK2822577T3 (en) | 2012-02-15 | 2019-04-01 | Bioverativ Therapeutics Inc | RECOMBINANT FACTOR VIII PROTEINS |
| ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| WO2013148329A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Charged nutritive proteins and methods |
| US9598474B2 (en) | 2012-03-26 | 2017-03-21 | Axcella Health, Inc. | Nutritive fragments, proteins and methods |
| US9605040B2 (en) | 2012-03-26 | 2017-03-28 | Axcella Health Inc. | Nutritive proteins and methods |
| AU2013240271A1 (en) | 2012-03-26 | 2014-10-02 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
| US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| ES2733911T3 (es) | 2013-08-08 | 2019-12-03 | Global Bio Therapeutics Inc | Dispositivo de sujeción para procedimientos minimamente invasivos |
| WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
| AU2014324897A1 (en) | 2013-09-25 | 2016-05-19 | Axcella Health Inc. | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
| HRP20211734T8 (hr) | 2014-11-21 | 2022-03-04 | Ascendis Pharma Endocrinology Division A/S | Dozni oblici dugodjelujućeg hormona rasta |
| WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
| AU2017257504A1 (en) | 2016-04-26 | 2018-10-25 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| NZ769677A (en) | 2018-05-18 | 2024-07-05 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| WO2020004368A1 (ja) | 2018-06-25 | 2020-01-02 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| CN109486847B (zh) * | 2018-12-17 | 2021-03-02 | 江南大学 | 基于人工串联启动子的枯草芽孢杆菌高效诱导表达系统 |
| WO2024175788A2 (en) | 2023-02-23 | 2024-08-29 | Micropep Technologies S.A. | Methods and compositions for production and purification of peptides |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3853833A (en) * | 1971-04-27 | 1974-12-10 | Hormone Res Foundation | Synthetic human growth-promoting and lactogenic hormones and method of producing same |
| US3853832A (en) * | 1971-04-27 | 1974-12-10 | Harmone Res Foundation | Synthetic human pituitary growth hormone and method of producing it |
| GB1521032A (en) * | 1974-08-08 | 1978-08-09 | Ici Ltd | Biological treatment |
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| NZ187300A (en) * | 1977-05-27 | 1982-08-17 | Univ California | Dna transfer vector and micro-organism modified to contain a nucleotide sequence equivalent to the gene of a higher organism |
| US4363877B1 (en) * | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
| CH630089A5 (de) * | 1977-09-09 | 1982-05-28 | Ciba Geigy Ag | Verfahren zur herstellung von siliciummodifizierten imidyl-phthalsaeurederivaten. |
| JPS5449837A (en) * | 1977-09-19 | 1979-04-19 | Kobashi Kogyo Kk | Safety apparatus of soil block making machine |
| US4407948A (en) * | 1977-09-23 | 1983-10-04 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
| ZA782933B (en) * | 1977-09-23 | 1979-05-30 | Univ California | Purification of nucleotide sequences suitable for expression in bacteria |
| US4321365A (en) * | 1977-10-19 | 1982-03-23 | Research Corporation | Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules |
| DK493878A (da) * | 1977-11-08 | 1979-05-09 | Genentech Inc | Fremgangsmaade og middel til mikrobiel polypeptid-udrykning |
| BR7807288A (pt) * | 1977-11-08 | 1979-06-12 | Genentech Inc | Processo para sintese de polinucleotidos |
| AT373279B (de) * | 1977-11-08 | 1984-01-10 | Genentech Inc | Verfahren zur herstellung eines rekombinationsclonbildungstraegers |
| US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| US4356270A (en) * | 1977-11-08 | 1982-10-26 | Genentech, Inc. | Recombinant DNA cloning vehicle |
| AT373281B (de) * | 1977-11-08 | 1984-01-10 | Genentech Inc | Verfahren zur herstellung eines strukturgens |
| US4652525A (en) * | 1978-04-19 | 1987-03-24 | The Regents Of The University Of California | Recombinant bacterial plasmids containing the coding sequences of insulin genes |
| US4565785A (en) * | 1978-06-08 | 1986-01-21 | The President And Fellows Of Harvard College | Recombinant DNA molecule |
| US4411994A (en) * | 1978-06-08 | 1983-10-25 | The President And Fellows Of Harvard College | Protein synthesis |
| IE48385B1 (en) * | 1978-08-11 | 1984-12-26 | Univ California | Synthesis of a eucaryotic protein by a microorganism |
| DE2963374D1 (en) * | 1978-10-10 | 1982-09-09 | Univ Leland Stanford Junior | Recombinant dna, method for preparing it and production of foreign proteins by unicellular hosts containing it |
| US4332892A (en) * | 1979-01-15 | 1982-06-01 | President And Fellows Of Harvard College | Protein synthesis |
| IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
| GR68404B (pt) * | 1979-06-01 | 1981-12-29 | Univ California | |
| US4898830A (en) * | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| GR70279B (pt) * | 1979-09-12 | 1982-09-03 | Univ California | |
| IL59690A (en) * | 1980-03-24 | 1983-11-30 | Yeda Res & Dev | Production of bovine growth hormone by microorganisms and modified microorganisms adapted to produce it |
| GR79124B (pt) * | 1982-12-22 | 1984-10-02 | Genentech Inc | |
| US4859600A (en) * | 1983-04-25 | 1989-08-22 | Genentech, Inc. | Recombinant procaryotic cell containing correctly processed human growth hormone |
| CA1267615A (en) * | 1984-08-27 | 1990-04-10 | Dan Hadary | Method for recovering purified growth hormones from genetically engineered microorganisms |
-
1979
- 1979-07-05 US US06/055,126 patent/US4342832A/en not_active Expired - Lifetime
-
1980
- 1980-06-12 IE IE1214/80A patent/IE50460B1/en not_active IP Right Cessation
- 1980-06-12 IE IE2194/84A patent/IE50462B1/en not_active IP Right Cessation
- 1980-06-12 IE IE2193/84A patent/IE50461B1/en unknown
- 1980-06-13 NZ NZ201312A patent/NZ201312A/xx unknown
- 1980-06-13 NZ NZ194043A patent/NZ194043A/xx unknown
- 1980-06-15 IL IL69492A patent/IL69492A/xx unknown
- 1980-06-15 IL IL60312A patent/IL60312A/xx unknown
- 1980-06-17 ZA ZA00803600A patent/ZA803600B/xx unknown
- 1980-06-19 CA CA000354359A patent/CA1164375A/en not_active Expired
- 1980-06-20 AU AU59498/80A patent/AU533697B2/en not_active Expired
- 1980-06-20 ZW ZW141/80A patent/ZW14180A1/xx unknown
- 1980-06-23 MX MX026650A patent/MX172674B/es unknown
- 1980-06-23 YU YU01635/80A patent/YU163580A/xx unknown
- 1980-06-24 DE DE3023627A patent/DE3023627A1/de not_active Ceased
- 1980-06-24 DE DE3050722A patent/DE3050722C2/de not_active Expired
- 1980-06-24 DE DE3050725A patent/DE3050725C2/de not_active Expired
- 1980-06-25 FI FI802030A patent/FI802030A/fi not_active Application Discontinuation
- 1980-06-25 FR FR8014108A patent/FR2460330B1/fr not_active Expired
- 1980-06-26 IT IT23070/80A patent/IT1131393B/it active Protection Beyond IP Right Term
- 1980-06-26 BE BE1/9864A patent/BE884012A/fr not_active IP Right Cessation
- 1980-06-27 CH CH4958/80A patent/CH661939A5/de not_active IP Right Cessation
- 1980-07-01 PL PL1980225376A patent/PL149278B1/pl unknown
- 1980-07-01 BG BG048346A patent/BG41135A3/xx unknown
- 1980-07-01 EP EP80103748A patent/EP0022242B1/en not_active Expired - Lifetime
- 1980-07-01 OA OA57150A patent/OA06562A/xx unknown
- 1980-07-01 AT AT80103748T patent/ATE82324T1/de not_active IP Right Cessation
- 1980-07-02 PT PT71487A patent/PT71487A/pt unknown
- 1980-07-02 EG EG80392A patent/EG14819A/xx active
- 1980-07-02 GR GR62345A patent/GR69320B/el unknown
- 1980-07-03 PH PH24236A patent/PH19814A/en unknown
- 1980-07-03 GB GB08234691A patent/GB2121047B/en not_active Expired
- 1980-07-03 WO PCT/US1980/000838 patent/WO1981000114A1/en unknown
- 1980-07-03 GB GB8021860A patent/GB2055382B/en not_active Expired
- 1980-07-03 BR BR8008736A patent/BR8008736A/pt unknown
- 1980-07-04 CS CS804809A patent/CS250652B2/cs unknown
- 1980-07-04 JP JP55092161A patent/JPH0612996B2/ja not_active Expired - Lifetime
- 1980-07-04 KR KR1019800002658A patent/KR830003574A/ko unknown
- 1980-07-04 ES ES493149A patent/ES8105386A1/es not_active Expired
- 1980-07-04 DD DD80244147A patent/DD210070A5/de unknown
- 1980-07-04 DD DD80244149A patent/DD210071A5/de unknown
- 1980-07-04 DD DD80222413A patent/DD157343A5/de unknown
- 1980-07-04 AR AR80281658A patent/AR244341A1/es active
-
1981
- 1981-02-02 ES ES499043A patent/ES499043A0/es active Granted
- 1981-02-20 NO NO81810608A patent/NO167673C/no unknown
- 1981-03-04 DK DK198100973A patent/DK173503B1/da not_active IP Right Cessation
- 1981-03-05 RO RO103596A patent/RO93374B/ro unknown
- 1981-08-26 US US06/296,099 patent/US4634677A/en not_active Expired - Lifetime
-
1982
- 1982-03-09 US US06/356,564 patent/US4601980A/en not_active Expired - Lifetime
- 1982-03-09 US US06/361,160 patent/US4604359A/en not_active Expired - Lifetime
- 1982-05-12 CS CS823457A patent/CS250655B2/cs unknown
-
1983
- 1983-01-17 FR FR8300612A patent/FR2518572B1/fr not_active Expired
- 1983-04-25 CA CA000426675A patent/CA1202256A/en not_active Expired
- 1983-06-01 YU YU01211/83A patent/YU121183A/xx unknown
- 1983-06-01 YU YU01212/83A patent/YU121283A/xx unknown
- 1983-08-14 IL IL69492A patent/IL69492A0/xx unknown
- 1983-08-24 AU AU18388/83A patent/AU1838883A/en not_active Abandoned
-
1984
- 1984-04-09 CS CS842708A patent/CS254973B2/cs unknown
- 1984-08-13 SG SG569/84A patent/SG56984G/en unknown
- 1984-09-13 KE KE3451A patent/KE3451A/xx unknown
- 1984-09-13 KE KE3446A patent/KE3446A/xx unknown
- 1984-09-13 KE KE3450A patent/KE3450A/xx unknown
- 1984-09-25 US US06/654,340 patent/US4658021A/en not_active Expired - Lifetime
- 1984-11-08 HK HK874/84A patent/HK87484A/xx not_active IP Right Cessation
- 1984-11-08 HK HK873/84A patent/HK87384A/xx not_active IP Right Cessation
- 1984-11-08 HK HK875/84A patent/HK87584A/xx not_active IP Right Cessation
-
1985
- 1985-01-16 FI FI850198A patent/FI850198L/fi not_active Application Discontinuation
- 1985-12-30 MY MY765/85A patent/MY8500765A/xx unknown
- 1985-12-30 MY MY763/85A patent/MY8500763A/xx unknown
- 1985-12-30 MY MY764/85A patent/MY8500764A/xx unknown
-
1986
- 1986-02-24 NO NO86860680A patent/NO167674C/no unknown
- 1986-11-12 KR KR1019860009542A patent/KR870000701B1/ko not_active IP Right Cessation
-
1989
- 1989-04-18 JP JP1099888A patent/JPH0648987B2/ja not_active Expired - Lifetime
-
1990
- 1990-10-18 DK DK251490A patent/DK172132B1/da not_active IP Right Cessation
-
1992
- 1992-09-25 JP JP4256344A patent/JP2622479B2/ja not_active Expired - Lifetime
-
1993
- 1993-06-29 NL NL930114C patent/NL930114I2/nl unknown
-
1994
- 1994-05-27 US US08/250,639 patent/US5424199A/en not_active Expired - Fee Related
-
1995
- 1995-06-01 US US08/457,282 patent/US5795745A/en not_active Expired - Fee Related
- 1995-11-29 JP JP7310696A patent/JPH08242881A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD157343A5 (de) | Mikrobielle expression von quasi-synthetischen genen | |
| DE3111405C2 (pt) | ||
| DE3486216T2 (de) | Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren. | |
| DE2848053A1 (de) | Synthetische dna und verfahren zu ihrer herstellung | |
| EP0602688B1 (de) | Methioninfreier G-CSF aus Prokaryonten | |
| DE2848052A1 (de) | Synthetische dna und verfahren zu ihrer herstellung | |
| US4898830A (en) | Human growth hormone DNA | |
| DD144560A5 (de) | Verfahren zur herstellung von synthetischen strukturgenen | |
| DE3687141T2 (de) | Verfahren zur herstellung von peptiden. | |
| DD208989A5 (de) | Verfahren zur synthetisierung von menschlichem insulin | |
| EP0453969B1 (de) | Verfahren zur Herstellung von Fremdproteinen in Streptomyceten | |
| DE3485923T2 (de) | Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid. | |
| DE3587205T2 (de) | Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle. | |
| DD210466A5 (de) | Verfahren zur herstellung eines rekombinanten plasmids | |
| EP0040466B1 (en) | Adaptor molecules for dna and their application to synthesis of gene-derived products | |
| DE3783305T2 (de) | Expressionsvektor fuer menschlichen insulinaehnlichen wachstumsfaktor-i. | |
| EP0393039B1 (en) | Process for producing peptides by specific cleavage of fusion proteins with collagenases obtained by genetic engineering | |
| DE3328793A1 (de) | Herstellung von sekretin | |
| DE69213282T2 (de) | Antiviren-Protein aus Mirabilis jalapa | |
| EP0198415B1 (de) | Veränderung der DNA-Sequenz zwischen Shine-Dalgarno-Sequenz und Startcodon des trp-Operons zur Steigerung der Proteinexpression |